About Quellis Biosciences
Quellis Biosciences is a Healthcare company based in Boston (United States) founded in 2017 by Vahe Bedian and Jonathan Violin, and was acquired by Astria in January 2021. Antibody-based therapeutics for rare diseases are developed and optimized. Quellis Biosciences has raised $17 million across 2 funding rounds from investors including Astria Therapeutics and Xontogeny. Its focus areas include Life Sciences, Rare Diseases, Drugs and Diversified. Its competitors include Moderna, BridgeBio and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Quellis Biosciences was established in 2017 in Boston, United States, within the biotechnology sector. Monoclonal antibodies targeting rare diseases are developed and refined. Xtend technology is employed to extend antibody half-life and minimize dosing frequency. Focus is placed on antibody-based drug development, with operations conducted from the companys location in the United States.
- Headquarters Boston, United States
- Founders Vahe Bedian, Jonathan Violin
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website quellisbio.com
- Acquired by Astria (Jan 2021)
- Total Equity Funding$17M (USD)
in 2 rounds
- Latest Funding Round$17M (USD), Series A
Dec 2019
- InvestorsAstria Therapeutics
& 1 more
- Acquired byAstria
(Jan 2021)
Funding Insights of Quellis Biosciences
Quellis Biosciences has successfully raised a total of $17M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $17 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17M
- Total Rounds 2
- Last Round Series A — $17M
- Investors Count 1
All 2 funding rounds of Quellis Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2019 | $17M | Series A | – | – | – |
| Nov 2017 | Seed | – | Xontogeny | – |
2 investors in total: 2 institutional.
Investors in Quellis Biosciences
Quellis Biosciences has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Astria Therapeutics and Xontogeny.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life science startups are accelerated through focused programs by Xontogeny. | 2016 | xontogeny.com | Boston, United States | |
Therapeutics for rare diseases, including hereditary angioedema inhibitors, are developed. | 2008 | astriatx.com | Boston, United States |
Investor details for Quellis Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Quellis Biosciences
2 people are tracked at Quellis Biosciences (2 in leadership).
| Name | Role | Group |
|---|---|---|
Vahe Bedian | Co-Founder | Leadership |
Jonathan Violin | Co-Founder | Leadership |
Complete people profiles for Quellis Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Quellis Biosciences
4 dated milestones of Quellis Biosciences across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Quellis Biosciences is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $17.0M.
- Exit Acquired by Astria.
Competitors of Quellis Biosciences
Quellis Biosciences has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Quellis Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Quellis Biosciences (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Quellis Biosciences
Complete news archive for Quellis Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Quellis Biosciences
Quellis Biosciences was founded in 2017.
Quellis Biosciences is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Quellis Biosciences is a funded company, having raised a total of $17M across 2 funding rounds to date.
Quellis Biosciences was established in 2017 in Boston, United States, within the biotechnology sector. Monoclonal antibodies targeting rare diseases are developed and refined. Xtend technology is employed to extend antibody half-life and minimize dosing frequency. Focus is placed on antibody-based drug development, with operations conducted from the companys location in the United States.
Quellis Biosciences's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Quellis Biosciences has 2 investors. Key investors include Astria Therapeutics, and Xontogeny.
Yes. Quellis Biosciences was acquired by Astria in January 2021.